EUVIMEDEUVIMED entdecken
Crossref

Prevalence and Prognostic Implications of Circulating Tumor Cells Among Patients Undergoing Neoadjuvant Chemotherapy for Early-Stage Breast Cancer

Mark Freeman, Alicja Prawdzic Senkowska, Rania Chehade, Sara Compaore, Giuseppe Di Caro, Nadine Hartmann, Richard Wenstrup, Ana Elisa Lohmann, William T Tran, Katarzyna J Jerzak

Clinical Breast Cancer · 2026-07 · 26 (7) · 24-29

DOI: 10.1016/j.clbc.2026.05.005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Breast Cancer, 2026-07. Verfasst von Mark Freeman und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Odette Cancer Centre, Sunnybrook Health Science Centre, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Neoplastic Cells, Circulating, Neoadjuvant Therapy, Breast Neoplasms, Neoplasm Recurrence, Local. Die Arbeit nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND Circulating tumor cells (CTCs) are frequently detected in patients with breast cancer, but key studies investigating their clinical significance in early-stage disease rely on less-sensitive methods for CTC detection. OBJECTIVE To evaluate the prevalence and prognostic implications of CTCs in patients undergoing NAC for early-stage breast cancer. DESIGN This was a single-center prospective cohort study. Patients with early-stage breast cancer who were planned to receive NAC were enrolled. METHODS CTCs were measured before NAC and again at least 4 weeks following definitive surgery using the Epic Sciences platform. Clinical, pathological, and treatment data were abstracted from electronic medical records and summarized. RESULTS A total of 40 patients comprised the analyzable study population. The median age at diagnosis was 53 years. Breast cancer subtypes included HER2+ (38%), hormone receptor-positive/HER2-negative (HR+/HER2-, 32%), and triple-negative breast cancer (TNBC, 25%). After a median follow-up of 39.8 months, only 5 patients (12%) had experienced disease recurrence. CTCs were detected in 82% of patients before treatment and 45% of patients after treatment (P = .001). All subgroups of patients had numerically lower rates of CTC prevalence post-treatment compared to pretreatment; subgroups in whom this difference was statistically significant included patients with TNBC (90% vs. 30%, P = .006), premenopausal patients (79% vs. 29%, P = .008), and patients who did not experience disease recurrence (80% vs. 43%, P = .001). CONCLUSION CTCs are more prevalent both before and after NAC than had previously been reported. The clinical significance of their persistence warrants further investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoplastic Cells, CirculatingNeoadjuvant TherapyBreast NeoplasmsNeoplasm Recurrence, LocalAntineoplastic Combined Chemotherapy ProtocolsHumansFemalePrognosisMiddle AgedProspective StudiesAdultNeoplasm StagingPrevalenceBiomarkers, TumorAgedErb-b2 Receptor Tyrosine KinasesFollow-Up StudiesTriple Negative Breast NeoplasmsChemotherapy, Adjuvant

Stichwörter der Autor:innen

BiomarkersCirculating tumor cellsEarly breast cancerHER2-positive breast cancerTriple negative breast cancer

Substanzen

Biomarkers, TumorErb-b2 Receptor Tyrosine KinasesERBB2 protein, human

Autor:innen und Institutionen

  • Department of Medicine, Odette Cancer Centre, Sunnybrook Health Science Centre, Toronto, Ontario, Canada.
  • Department of Oncology, Queen's University, Kingston, Ontario, Canada.
  • Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, Canada.
  • Epic Sciences, San Diego, CA.
  • Division of Medical Oncology, Department of Oncology, London Health Sciences Centre, Western University, London, Ontario, Canada.
  • Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. Electronic address: william.tran@sunnybrook.ca.

Zitieren

APA

Freeman, M., Prawdzic Senkowska, A., Chehade, R., Compaore, S., Di Caro, G., Hartmann, N., Wenstrup, R., Lohmann, A. E., Tran, W. T., & Jerzak, K. J. (2026). Prevalence and Prognostic Implications of Circulating Tumor Cells Among Patients Undergoing Neoadjuvant Chemotherapy for Early-Stage Breast Cancer. Clinical Breast Cancer, 26(7), 24-29. https://doi.org/10.1016/j.clbc.2026.05.005

Vancouver

Freeman M, Prawdzic Senkowska A, Chehade R, Compaore S, Di Caro G, Hartmann N, et al. Prevalence and Prognostic Implications of Circulating Tumor Cells Among Patients Undergoing Neoadjuvant Chemotherapy for Early-Stage Breast Cancer. Clinical Breast Cancer. 2026;26(7):24-29. doi:10.1016/j.clbc.2026.05.005

BibTeX
@article{Freeman2026,
  author = {Freeman, Mark and Prawdzic Senkowska, Alicja and Chehade, Rania and Compaore, Sara and Di Caro, Giuseppe and Hartmann, Nadine and Wenstrup, Richard and Lohmann, Ana Elisa and Tran, William T and Jerzak, Katarzyna J},
  title = {Prevalence and Prognostic Implications of Circulating Tumor Cells Among Patients Undergoing Neoadjuvant Chemotherapy for Early-Stage Breast Cancer},
  journal = {Clinical Breast Cancer},
  year = {2026},
  volume = {26},
  number = {7},
  pages = {24--29},
  doi = {10.1016/j.clbc.2026.05.005}
}
Kostenlos starten →